Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

News

KarMMa-3 Trial Update: Use of Idecabtagene Vicleucel in Resistant Multiple Myeloma
Brexucabtagene Autoleucel in Resistant Mantle Cell Lymphoma: Real-World Versus ZUMA-2 Data
Atezolizumab Plus Bevacizumab: A Potential Option for Certain Patients With Nonsquamous Lung Cancer
Predicting Performance and Targets for Immunotherapy in Liver Cancer
Adding Pembrolizumab to Docetaxel in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2023: Hormone Therapy Plus an Anti-PSMA Antibody Labeled With Lu-177 in Nonmetastatic Prostate Cancer
ASCO GU 2023: Extended Follow-up From CheckMate 274 With Nivolumab for High-Risk Urothelial Carcinoma
ELARA Trial: Is Tisagenlecleucel of Benefit in Relapsed or Refractory Follicular Lymphoma?
ASCO GU 2023: Update From KEYNOTE-057 on Pembrolizumab Monotherapy for Aggressive Bladder Cancer
ASCO GU 2023: Overall Survival Update From IMvigor130 on Atezolizumab Versus Chemotherapy for Advanced Urothelial Carcinoma
18-Month Follow-up on Ciltacabtagene Autoleucel in Patients With Multiple Myeloma
ASCO GU 2023: Nivolumab Plus Ipilimumab After Chemotherapy for Resistant Prostate Cancer
ASCO GU 2023: Predicting Outcomes With Enfortumab Vedotin in Advanced Urothelial Carcinoma
Comparison of Standard Therapies for Transplantation-Ineligible Patients With Myeloma
Lenvatinib After Immunotherapy for Advanced Hepatocellular Carcinoma
Potential Genomic Mechanisms of Resistance to Targeted Immunotherapy for Myeloma
Adding Dual Immune Blockade to Chemotherapy for HER2-Negative Breast Cancer
Salvage Therapies After Myeloma Progression on CAR T-Cell Therapy
ASCO GI 2023: Adding Envafolimab to Lenvatinib Plus TACE in Unresectable Liver Cancer
TALENT Trial: Neoadjuvant T-DXd for HER2-Low, HR-Positive Breast Cancer
ASCO GI 2023: Patient-Reported Outcomes With Lenvatinib Plus Pembrolizumab in Advanced Liver Cancer
CAR T-Cell Therapy After BCMA-Targeted Therapy for Resistant Multiple Myeloma
Sacituzumab Govitecan-hziy Approved by the FDA for HR-Positive, HER2-Negative Breast Cancer
Final Analysis of Novel Triplet Combination in Resistant Follicular Lymphoma
Immunologic Profile of Patients With High-Risk Smoldering Myeloma
T-DXd Versus Conventional Regimens for T-DM1–Pretreated, HER2-Positive Metastatic Breast Cancer
FDA Approves Pembrolizumab as Adjuvant Therapy for NSCLC
Can Decreased Nectin-4 Expression Predict Resistance to Enfortumab Vedotin in Urothelial Carcinoma?
ASCO GI 2023: Health-Related Quality-of-Life Outcomes With Tislelizumab Versus Sorafenib in Liver Cancer
Extended Consolidation Therapy After ASCT for Ultra–High-Risk Multiple Myeloma
Updated Results From Cohort C of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Multiple Myeloma
Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.